RXRX ends the week with a contradiction at its core: short interest near multi-month highs, a lending market that has run completely dry, and options traders piling into calls rather than puts.
The lending picture remains extreme. Availability has been at 0% for two consecutive sessions — every share in the borrow pool is already lent out. That matched a similar episode on June 15, recovered briefly to 23% on June 18, and has since collapsed back to zero. New short sellers cannot add exposure; the market is locked. Yet borrowing costs have eased, not spiked — the cost to borrow has fallen roughly 13% over the week to just under 1%. That divergence suggests existing positions were locked in cheaply before the pool dried up, rather than fresh short demand driving up rates. The ORTEX short score confirms the pressure: it has held above 81 all week, closing at 82.2 on Tuesday before ending the period at 82.2 — placing RXRX in the bottom 2nd percentile for short-score rank across the coverage universe.
Short interest itself tells a story of accumulation. The SI % of free float climbed 11.2% over the week to 35.8% — the highest level in months — after a jump on June 24 when an additional ~16 million shares appeared short in a single session. Official FINRA data as of June 15 confirmed 184 million shares short with 8.4 days to cover. That is a meaningful short base for a stock trading at $3.67. And yet, options traders are not positioned defensively. The put/call ratio moved to 0.19 — barely above its 20-day average of 0.18 but running near the 52-week low of 0.17, the opposite of where it would sit if options participants were bracing for a fall. The z-score of 2.0 reflects a slight recent uptick in put demand, but the absolute level of the PCR remains one of the most call-skewed readings of the past year.
The Street is split and its most recent views are dated. The last meaningful analyst action was Morgan Stanley nudging its target from $5.00 to $5.50 in mid-May, maintaining Equal-Weight. JPMorgan holds Overweight with a $10 target set in late April, while Needham has kept its Buy and $8 target unchanged. The mean price target across the group is $6.64 — nearly 81% above the current price — but that gap should be read cautiously given that most of these targets were set before the stock's continued slide into the low $3s. Bulls point to the AI-drug discovery platform, Sanofi and Roche partnerships, and a cash runway into early 2028. Bears emphasize that clinical programs are still early-stage, competition in ML-driven pharma is intensifying, and the platform's value ultimately depends on partner milestones rather than internal catalysts. The price-to-book at 2.9x and deeply negative P/E and EV/EBITDA multiples reflect a company priced on option value, not current earnings.
Insider activity has been consistently one-directional. The Founder and Chairman, CFO, Chief Commercial Officer, and Chief Scientific Officer have all sold shares in May and June — mostly small ticket transactions in the $12,000–$190,000 range, likely tied to compensation plan vesting. None were large enough in isolation to read as a conviction signal, and the 90-day net is a modest $1.8 million of net selling across roughly a dozen transactions. The pattern is consistent with routine plan-based sales rather than a coordinated exit.
The stock gained 16% over the week to close at $3.67, outpacing close peer EDIT (up 17%) and NTLA (up 11%), while CRSP added only 1%. That bounce came against a backdrop of rising short interest and a locked borrow market — a combination that raises the question of whether some covering drove the move. With the next earnings event scheduled for August 5, what to watch now is whether availability remains at zero into that print, or whether the lending pool briefly reopens — and whether short interest begins to ease or continues to build heading into results.
See the live data behind this article on ORTEX.
Open RXRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
